BiotechTube
TeamedOn

TeamedOn

San Francisco, United States· Est.
teamedon.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

TeamedOn is a private, pre-clinical stage biotech founded in 2020 and headquartered in Rockville, MD, USA, focusing on gene therapies for rare ophthalmic diseases. Its lead program targets X-linked Retinoschisis (XLRS), an orphan disease with no effective treatment, utilizing a viral vector-based gene replacement strategy. The company is led by a small team with extensive industry experience in drug development and is supported by key clinical advisors from leading ophthalmology institutions. TeamedOn operates as a pre-revenue therapeutics developer seeking partnerships to advance its pipeline.

OphthalmologyRare Diseases

Technology Platform

AAV (adeno-associated virus) vector-based gene replacement therapy for monogenic retinal disorders.

Opportunities

The company is targeting X-linked Retinoschisis (XLRS), a monogenic orphan disease with no effective treatment, representing a clear unmet need and potential for regulatory incentives.
The established precedent of high-value, one-time gene therapies in ophthalmology (e.g., Luxturna) validates the commercial model for successful treatments in rare retinal diseases.

Risk Factors

The lead program is in pre-clinical stages with unproven efficacy in humans, and previous clinical trials for XLRS gene therapy have not shown significant improvement, indicating scientific risk.
As a pre-revenue private company, TeamedOn faces significant financial risk and is dependent on raising additional capital or securing partnerships to advance its pipeline.

Competitive Landscape

TeamedOn operates in the competitive field of ocular gene therapy, where several companies are developing treatments for various inherited retinal diseases. Its specific focus on XLRS places it in a narrower niche, but it must compete for funding, partnerships, and ultimately, clinical success against other gene therapy developers and modalities targeting retinal disorders.

More companies in United States →